Project Grant R01CA314354
Award Date 7/22/26
Completion Date 6/30/31
Dollars Obligated $737K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Cancer Institute awarded the Beckman Research Institute of The City of Hope $280,931 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support investigator-initiated research on skeletal muscle health and impaired glucose tolerance in adolescent and young adult hematopoietic cell transplantation survivors. The award funds research examining how HCT-related exposures—including total body irradiation, corticosteroid exposure, graft-versus-host disease,...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $393,750 to the University of California, Los Angeles (UCLA) on September 22, 2025, under the Aging Research program (CFDA 93.866) to conduct a prospective cohort study investigating how aggressive cancer treatments affect physical function in older adults with gastroesophageal cancer (GEC). The research will enroll patients aged 60 years and older who are initiating systemic treatment (chemotherapy,...
- The National Cancer Institute awarded the University of California, Los Angeles $368,156 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate radiation-induced cellular reprogramming in the developing human brain and identify neuroprotective interventions. The research addresses cognitive decline following cranial radiotherapy for brain tumors by testing the hypothesis that radiation drives neural stem and progenitor cells to transdifferentiate into...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute awarded Duke University $433,658 under the Cancer Treatment Research program on September 1, 2026, to investigate how toll-like receptor 4 activity in mesenchymal stromal cells contributes to skeletal muscle decline and fibrosis induced by cancer treatment. The research addresses accelerated frailty in pediatric cancer survivors who receive fractionated X-ray irradiation. The award funds a murine model study examining radiation-induced muscle weakness, myofiber...
- The National Cancer Institute awarded a $695,155 Cooperative Agreement to Fred Hutchinson Cancer Center on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize post-transplantation cyclophosphamide (PTCY) dosing for hematopoietic cell transplantation with peripheral blood stem cell grafts. The award funds a phase I/II clinical trial examining PTCY dose de-escalation in recipients of HLA-matched or HLA-haploidentical donor transplants using reduced-intensity...
- The National Institutes of Health National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $667,933 on July 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate acceptance and commitment therapy (ACT) as an intervention to improve psychological resilience and physical function in patients undergoing allogeneic hematopoietic stem cell transplantation. The project addresses the significant functional and...
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $1.561 million on April 15, 2026, under the Aging Research program (CFDA 93.866) to investigate immune aging phenotypes in adult survivors of childhood hematologic malignancies and their association with chronic health conditions including congestive heart failure, coronary artery disease, and frailty. The research applies high-dimensional immunological approaches to characterize distinct aging-associated immune cell...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $666,852 on July 24, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the regulation of age-related chronic inflammation in cancer immunity. The research elucidates mechanisms by which a thymic hormone reduces pro-inflammatory cytokine production from myeloid cells in aged organisms, with the goal of improving tumor control, survival outcomes, and sensitivity to...
- The National Cancer Institute awarded the University of California, Los Angeles $528,265 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct fragment-based drug discovery against oncogenic microRNA precursors using high-throughput crystallography. The funded research targets the precursor structures (pre-miRNAs) of oncogenic microRNAs (oncomirs) that fold into hairpin configurations recognized and cleaved by microRNA processing enzymes. The project performs...